| 26.0801 -0.305 (-1.15%) | 04-16 15:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.18 |
1-year : | 34.86 |
| Resists | First : | 28.4 |
Second : | 29.85 |
| Pivot price | 27.68 |
|||
| Supports | First : | 26.07 |
Second : | 21.69 |
| MAs | MA(5) : | 27.05 |
MA(20) : | 27.98 |
| MA(100) : | 25.82  |
MA(250) : | 23.57 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 14.8 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 31.98 | Low : | 16.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BBC ] has closed above bottom band by 1.4%. Bollinger Bands are 5.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.28 - 26.49 | 26.49 - 26.64 |
| Low: | 25.63 - 25.87 | 25.87 - 26.03 |
| Close: | 25.77 - 26.14 | 26.14 - 26.39 |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Sun, 07 Apr 2024
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Stock Price Up 1.2% - Defense World
Mon, 04 Mar 2024
Last Week, Virtus LifeSci Biotech Clinical Trials ETF Climbed 10%. Why? - Opto RoW
Tue, 05 Jul 2022
Biotech ETFs Are Making a Comeback - ETF Trends
Fri, 01 Jul 2022
Best Performing ETFs For June 2022 - ETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet
Tue, 31 Dec 2019
15 Best Performing ETFs of 2019 - ETF Trends
Thu, 12 Dec 2019
ETF of the Week: Virtus LifeSci Biotech Clinical Trials ETF (BBC) - ETF Trends
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|